Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function

A Multicentric, Open-label, Non-randomized Study to Evaluate the Pharmacokinetic, Safety and Tolerability of ITF2357 Given as an Oral Single 50 mg Dose in Participants With Chronic Hepatic Impairment Relative to Matched Participants With Normal Hepatic Function

This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

Study Overview

• Status: Completed
• Conditions: Hepatic Impairment
• Intervention / Treatment: Drug: ITF2357

Detailed Description

This study evaluated the effect of mild and moderate hepatic impairment (HI) on the pharmacokinetics of ITF2357 and its metabolites, along with the safety and tolerability in this patient population.

The total number of participants enrolled in the study was 24 subjects:

• 8 participants with mild HI (Child-Pugh class A)
• 8 participants with moderate HI (Child-Pugh class B)
• 8 participants with normal hepatic function (control group)

Each participant went through:

• A screening period from Day (D)-28 to D-2
• One 6-day/5-night inpatient period (from D-1 evening to D5 morning)
• An end-of-study evaluation to be done on D10 (±1 day).

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• Bulgaria
  • Sofia, Bulgaria, 1606
    • MC COMAC Medical Ltd
  • Sofia, Bulgaria, 1612
    • MC COMAC Medical Ltd
• France
  • Rennes, France, 35042
    • Biotrial

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria for Participants with HI:

1. Male or female participants, between 18 and 75 years of age, inclusive.
2. Body weight between 60.0 and 110.0 kg, inclusive if male, and between 50.0 and 100.0 kg, inclusive if female, body mass index (BMI) between 18.00 and 34.99 kg/m2, inclusive.
3. Stable chronic liver disease assessed by medical history, physical examination, laboratory values.
4. Vital signs after 10 minutes resting in supine position within the following range [or if out of range, considered not clinically significant (NCS) by the Investigator]: 95 mmHg < systolic blood pressure (SBP) < 180 mmHg; 45 mmHg < diastolic blood pressure (DBP) < 100 mmHg; 40 bpm < heart rate (HR) < 100 bpm.
5. 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances were participants enrolled with corrected QT according to Fridericia (QTcF) > 450 ms.
6. Any confirmed clinically relevant abnormal laboratory test that, on Investigator's judgment, was inconsistent with the subject's status as a patient with hepatic impairment. However, renal function assessed using the estimated glomerular filtration rate (eGFR) calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula had to be strictly above 60 mL/min/1.73m².
7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.

8. Female participants of non-childbearing potential, defined as one of the following:

   1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at screening;
   2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.

9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to Clinical Trials Coordination Group [CTCG] recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:

   1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
   2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
   3. intrauterine device (IUD);
   4. intrauterine hormone-releasing system (IUS);
   5. bilateral tubal occlusion;
   6. vasectomized partner;
   7. sexual abstinence (when in line with the preferred and usual subject's lifestyle).

   Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception.

10. Had given written informed consent prior to any procedure related to the study.
11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
12. Not under any administrative or legal supervision.
13. For moderate HI cohort: Child-Pugh total score ranging from 7 to 9, inclusive.
14. For mild HI cohort: Child-Pugh total score ranging from 5 to 6, inclusive.
15. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.

Exclusion Criteria for Participants with HI:

1. Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness.
2. Hepatocarcinoma.
3. Acute hepatitis.
4. Hepatic encephalopathy grade 2, 3, and 4.
5. Blood donation within 2 months before inclusion.
6. Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 30 mmHg within 3 minutes when changed from supine to standing position.
7. Presence or history of drug hypersensitivity, or allergic disease, except seasonal rhinitis, diagnosed and treated by a physician.
8. History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion.
9. Smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking over 5 cigarettes per day from D-1 and throughout the entire institutionalization (i.e. up to D5).
10. Excessive consumption of beverages with xanthine bases (more than 4 cups or glasses per day).
11. If female, pregnancy [defined as positive β-human choriogonadotropin (β-HCG) blood test] or breast feeding.
12. Any significant change in chronic treatment medication within 14 days before inclusion.

13. Consumption of PgP or BCRP potent inducers or inhibitors that could impact the PK of the investigational product within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication before inclusion.

    Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the EOS visit is completed.

14. Any vaccination, including COVID-19 within 2 weeks before inclusion.
15. Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
16. Any participant in the exclusion period of a previous study according to applicable regulations.
17. Any participant who could not be contacted.
18. Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
19. Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
20. Positive results on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates) unless this result was secondary to a documented medical prescription (only for benzodiazepines and cannabinoids).
21. Positive alcohol breath test.
22. Any consumption of citrus fruits (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion.

23. Medications that prolong the QTc interval (refer to the list provided in Section 12 of Appendix 16.1.1) within 14 days before inclusion or within 7 times the elimination half-life before inclusion.

    Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the last ECG at EOS is completed.

24. Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death.

Inclusion Criteria for Participants with normal hepatic function:

1. Male or female participants, between 18 and 75 years of age, inclusive.
2. Body weight within 10% of the mean body weight of the participants with moderate HI, and BMI between 18.00 and 34.99 kg/m2, inclusive.
3. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
4. Vital signs after 10 minutes resting in the supine position within the following range (or if out of range, considered NCS by the Investigator): 95 mmHg < SBP < 140 mmHg; 45 mmHg < DBP < 90 mmHg; 40 bpm < HR < 100 bpm.
5. 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances participants could have been enrolled with QTcF > 450 ms.
6. Laboratory parameters within the normal range, unless the Investigator considered an abnormality to be clinically irrelevant for healthy participants, except in the case of platelets, white blood cells and hemoglobin below lower limit of normal (LLN). However serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase), total bilirubin (unless the participant has documented Gilbert's syndrome, with a maximum bilirubin level lower than 3 x upper limit of normal (ULN), and any parameter for which there was an explicit stopping rule could not exceed the upper laboratory range; renal function assessed using the eGFR calculated by the 2021 CKD-EPI formula had to be strictly above 60 mL/min/1.73m².
7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.

8. Female participants of non-childbearing potential, defined as one of the following:

   1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and FSH in the range for menopausal female confirmed by blood test according to current local standards at screening.
   2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.

9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to CTCG recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:

   1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
   2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
   3. intrauterine device (IUD);
   4. intrauterine hormone-releasing system (IUS);
   5. bilateral tubal occlusion;
   6. vasectomized partner;
   7. sexual abstinence (when in line with the preferred and usual subject's lifestyle).

   Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM were not acceptable methods of contraception.

10. Had given written informed consent prior to any procedure related to the study.
11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
12. Not under any administrative or legal supervision.
13. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.

Exclusion Criteria for Participants with HI:

1. Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness.
2. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
3. Blood donation within 2 months before inclusion.
4. Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 20 mmHg within 3 minutes when changed from supine to standing position.
5. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician, except seasonal rhinitis.
6. History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion.
7. Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking from D-1 and throughout the entire institutionalization (i.e. up to D5).
8. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
9. If female, in a status of pregnancy (defined as positive β-HCG blood test), or breast-feeding.
10. Any medication (including PgP or BCRP inducers or inhibitors, or omeprazole) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication (except HRT and contraception when applicable), any vaccination within the last 28 days (except COVID-19 vaccination) and any biologics (antibody or its derivatives) given within 4 months before inclusion.
11. Any vaccination, including COVID-19 within 2 weeks before inclusion.
12. Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
13. Any participant in the exclusion period of a previous study according to applicable regulations.
14. Any participant who could not be contacted.
15. Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
16. Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-HIV1 and anti-HIV2 Ab.
17. Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
18. Positive alcohol breath test.
19. Any consumption of citrus (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion.
20. Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mild HI; Patients with mild HI (Child-Pugh class A)	Drug: ITF2357; ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose; Other Names: Givinostat; Givinostat hydrochloride monohydrate
Experimental: Moderate HI; Patients with moderate HI (Child-Pugh class B)	Drug: ITF2357; ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose; Other Names: Givinostat; Givinostat hydrochloride monohydrate
Experimental: Healthy Volunteers; Participants with normal hepatic function (control group)	Drug: ITF2357; ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose; Other Names: Givinostat; Givinostat hydrochloride monohydrate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax of ITF2357	Maximum plasma concentration observed	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUClast of ITF2357	Area under the plasma concentration versus time curve to the real time tlast	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf of ITF2357	Area under the plasma concentration versus time curve extrapolated to infinity	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tmax of ITF2357	Time to reach Cmax	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
t1/2 of ITF2357	Apparent terminal half-life	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
CL/F of ITF2357	Apparent total plasma clearance from plasma	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Vz/F of ITF2357	Apparent volume of distribution	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Cmax of ITF2357 Metabolites	Maximum plasma concentration observed	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUClast of ITF2357 Metabolites	Area under the plasma concentration versus time curve to the real time tlast	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf of ITF2357 Metabolites	Area under the plasma concentration versus time curve extrapolated to infinity	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Tmax of ITF2357 Metabolites	Time to reach Cmax	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
t1/2 of ITF2357 Metabolites	Apparent terminal half-life	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Fu of ITF2357 and Its Metabolites	Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-last,u of ITF2357 and Its Metabolites	Unbound area under the plasma concentration versus time curve to the real time Tlast	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf,u of ITF2357 and Its Metabolites	Unbound area under the plasma concentration versus time extrapolated to infinity	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Cmax,u of ITF2357 and Its Metabolites	Unbound maximum plasma concentration observed	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
CL/Fu of ITF2357	Unbound apparent total plasma clearance	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Vz/Fu of ITF2357	Unbound apparent volume of distribution	Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Incidence of Treatment Emergent Adverse Events (TEAEs)	Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment.	From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Treatment-Related TEAEs	Number of participants with at least one related TEAEs	From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Severity of Treatment Emergent Adverse Events (TEAEs)	Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event).	From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of TEAEs Leading to Withdrawal From the Study	Number of participants with at least one TEAE leading to withdrawal from the study	From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Serious TEAEs (SAEs)	Number of participants with at least one Serious TEAE	From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality	Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).	From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Vital Signs Abnormality	Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min).	From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Electrocardiogram Abnormality	Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec)	From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Physical Examination Abnormality	Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement.	From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

Collaborators and Investigators

• Sponsor: Italfarmaco
• Collaborators: Biotrial

Study record dates

Study Major Dates

• Study Start (Actual): May 29, 2025
• Primary Completion (Actual): August 14, 2025
• Study Completion (Actual): August 14, 2025

Study Registration Dates

• First Submitted: December 6, 2024
• First Submitted That Met QC Criteria: December 12, 2024
• First Posted (Actual): December 16, 2024

Study Record Updates

• Last Update Posted (Actual): June 18, 2026
• Last Update Submitted That Met QC Criteria: May 22, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Hepatic impairment
• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Histone Deacetylase Inhibitors; givinostat hydrochloride; givinostat
• Other Study ID Numbers: ITF/2357/60; 2024-513577-43-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No